Current Federal Status of 7-OH and MGM-15

As of August 2023, the DEA announced its intention to temporarily ban certain substances related to 7-hydroxymitragynine (7-OH), classifying them as Schedule I substances under the Controlled Substances Act. This includes synthetic derivatives such as MGM-15. The temporary ban aims to address public health concerns regarding the abuse potential of these substances.

While the DEA’s announcement sparked significant public interest and concern, it is important to note that the final scheduling process has yet to be completed. Currently, 7-OH is not federally illegal, but the implications of the ban could lead to significant restrictions in the future.

Change Log

This log provides a reverse-chronological list of significant events relating to the evolving situation of 7-OH and MGM-15.

• July 1, 2026: The DEA announced its intent to place 7-OH and related synthetic compounds into Schedule I, pending completion of the scheduling review.
• June 2026: Public health calls increased regarding the dangers associated with heightened levels of 7-OH.
• May 2026: The HHS and FDA issued warnings outlining the risks of certain enhanced kratom products.
• April 2026: A petition for public comment was opened to gather feedback before moving forward with any bans.
• March 2026: State health departments began issuing alerts concerning localized risks associated with high-potency 7-OH products.

Current Threshold and Effective Date

The specific threshold for 7-OH products has yet to be defined publicly. Once established, the threshold will likely dictate which products would be subject to the proposed ban.

As for the effective date of the ban, no definitive timeline has been provided as of now.

State Developments

Several states are taking independent actions regarding 7-OH and MGM-15, each implementing their restrictions based on local health assessments:

• California has launched specific regulations aimed at high-potency kratom products, including a temporary moratorium.
• Florida and New York are evaluating similar actions amidst rising health concerns.
• Multi-state coalitions are forming to address the growing concerns about the public health implications of 7-OH products.

Litigation and Legislation

Legal proceedings and legislative measures relating to the status of 7-OH are ongoing. A collection of individuals and organizations are pursuing litigation to challenge potential scheduling, arguing that these measures may infringe on consumer rights.

Enforcement and FDA Warnings

The FDA, alongside the DEA, has been actively warning against the abuse of kratom products, including 7-OH and MGM-15. Enforcement actions may escalate should products exceed the defined thresholds.

Merchant-Account Consequences

Businesses selling 7-OH may face increased merchant-account scrutiny as credit card processors adapt their risk assessment protocols. This may result in new restrictions for brands that fail to comply with the evolving landscape.

Scientific Publications

Research into 7-OH and its effects is ongoing. Recent publications are examining its pharmacology and abuse potential, contributing to public health discussions.

Withdrawal Resources

For users experiencing withdrawal symptoms from kratom products, numerous resources are available, including hotlines and clinics that specialize in addiction recovery.

Misinformation Corrections

Amid these discussions, misinformation about 7-OH and MGM-15 is prevalent. It’s critical to ensure sources are verified and accurate to avoid confusion about product legality and effects.